Combination therapy with WPRE-enhanced DNA vaccine and boosts with 14.18–IL-2 induces complete protection from metastatic neuroblastoma
| Treatment . | Liver weight . | Metastatic foci . |
|---|---|---|
| mTH-WPRE + ch14.18–IL-2 | 898 ± 109 | 0, 0, 0, 0, 0, 0 |
| Empty vector | 3500 ± 573 | >250, >250, >250, >250, 24, 16 |
| mTH | 3080 ± 953 | >250, >250, >250, 1, 2 |
| mTH + ch14.18–IL-2 | 1166 ± 68 | 7, 5, 0, 0, 0, 0 |
| mTH-WPRE | 1250 ± 113 | 7, 3, 0, 0, 0, 0 |
| ch14.18–IL-2 | 2133 ± 408*,† | >250, >250, >250, 35, 18, 3 |
| Treatment . | Liver weight . | Metastatic foci . |
|---|---|---|
| mTH-WPRE + ch14.18–IL-2 | 898 ± 109 | 0, 0, 0, 0, 0, 0 |
| Empty vector | 3500 ± 573 | >250, >250, >250, >250, 24, 16 |
| mTH | 3080 ± 953 | >250, >250, >250, 1, 2 |
| mTH + ch14.18–IL-2 | 1166 ± 68 | 7, 5, 0, 0, 0, 0 |
| mTH-WPRE | 1250 ± 113 | 7, 3, 0, 0, 0, 0 |
| ch14.18–IL-2 | 2133 ± 408*,† | >250, >250, >250, 35, 18, 3 |
Differences in liver weights of mice that received the combination therapy, mTH-WPRE vaccination, and ch14.18–IL-2 boost were statistically significant compared with the groups of mice that received either mTH plus boosts with the ch14.18–IL-2 or mice that were immunized with the mTH-WPRE vaccine alone.
P = .028.
P = .02